Genitourinary Cancers Articles | Page 2

Prostate Cancer Screening and Surveillance Continue to Evolve
William K. Kelly, DO, discusses the evolving imaging techniques and emerging therapeutic approaches in prostate cancer.
Expert Discusses Bone-Targeting Agents in Prostate Cancer
Robert B. Den, MD, discusses bone-targeting agents in prostate cancer and the potential future of combinations.
Genetic Testing Helps Guide Treatment in Prostate Cancer
Veda Giri, MD, discusses the developing role of genetic testing for the screening and management of patients with prostate cancer.
European Panel Backs New Nivolumab Dosing Schedules
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended adding the option of a 4-week dosing schedule to the label for nivolumab for the treatment of patients with advanced melanoma and previously treated renal cell carcinoma (RCC). 
FDA Grants Enfortumab Vedotin Breakthrough Designation for Urothelial Carcinoma
The FDA has granted enfortumab vedotin a breakthrough therapy designation for patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint therapy. 
Gomella Gives Predictions for Prostate Cancer Advances in 2018
Leonard G. Gomella, MD, shares his insight on this year's expected advances in the field of prostate cancer.
Novel Lenvatinib Combinations Tested in Frontline RCC
The current standard-of-care therapy for patients with clear cell renal cell carcinoma is sunitinib, but many patients relapse or don't have responses to the drug.
The FDA has granted a priority review to a supplemental new drug application (sNDA) for enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer.
Expert Highlights Immunotherapy Success in GU Cancers
Ani S. Balmanoukian, MD, discusses developments in genitourinary malignancies with promising immunotherapy breakthroughs in renal cell carcinoma and urothelial carcinoma.
FDA Grants Erdafitinib Breakthrough Designation for Urothelial Carcinoma
The FDA has granted a breakthrough therapy designation to erdafitinib for the treatment of metastatic urothelial carcinoma.
Publication Bottom Border
Border Publication